1
|
Mojiri-Forushani H, Khajehali E, Adelipour M, Mohammadi A. Inhibitory effects of fluoxetine on the secretion of inflammatory mediators and JAK/STAT3 and JNK/TLR4 gene expression. Mol Biol Rep 2023; 50:2231-2241. [PMID: 36571654 PMCID: PMC9791631 DOI: 10.1007/s11033-022-08219-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 12/16/2022] [Indexed: 12/27/2022]
Abstract
BACKGROUND Selective serotonin reuptake inhibitors (SSRIs) are the most common class of medicines used for the treatment of major depression. Recent studies have reported an association between depression and inflammation and suggested the significant effects of SSRIs on inflammatory processes. METHODS The current study aimed to evaluate the effects of fluoxetine, an SSRI, on the level of inflammatory cytokines, including interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), in the rat serum and RAW264.7 mouse macrophage cell line, using ELISA sandwich assays. Also, the expression of inflammatory genes, including JAK/STAT3 and TLR4/JNK, was examined in macrophages, using real-time quantitative reverse transcription PCR to determine the potential mechanism of fluoxetine in inflammation. The rats received fluoxetine (10, 20, and 40 mg/kg) 30 min before lipopolysaccharide (LPS) treatment for 90 min. The cells received different doses of fluoxetine (5, 10, and 20 µg/mL) before stimulation with LPS for 24 or 48 h. RESULTS The serum concentrations of IL-1β, IL-6, and TNF-α were reduced in rats and cells treated with fluoxetine. Following fluoxetine administration, the expression of JAK/STAT3 and TLR4/JNK genes was significantly decreased in the RAW264.7 cells treated with LPS for 24 h. However, after 48 h of treatment with LPS, fluoxetine failed to diminish the elevated expression of JAK and JNK genes, while it significantly decreased the expression of STAT3 and TLR4 genes. CONCLUSION The findings revealed that fluoxetine has anti-inflammatory properties, mainly due to the reduction of inflammatory cytokines and inhibition of JAK/STAT3 and TLR4/JNK gene expression in macrophages.
Collapse
Affiliation(s)
| | - Elham Khajehali
- Department of Anatomy & Physiology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Victoria, 3010, Australia.
| | - Maryam Adelipour
- Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | | |
Collapse
|
2
|
Forth E, Buehner B, Storer A, Sgarbossa C, Milev R, Chinna Meyyappan A. Systematic review of probiotics as an adjuvant treatment for psychiatric disorders. Front Behav Neurosci 2023; 17:1111349. [PMID: 36844651 PMCID: PMC9947154 DOI: 10.3389/fnbeh.2023.1111349] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 01/20/2023] [Indexed: 02/11/2023] Open
Abstract
Introduction Many psychiatric illnesses have been linked to the gut microbiome, with supplements such as probiotics showing some efficacy in alleviating the symptoms of some psychiatric illnesses. The aim of this review is to evaluate the current literature investigating the effects of adjuvant probiotic or synbiotic administration in combination with first-line treatments for psychiatric illnesses. Method A systematic search of four databases was conducted using key terms related to treatments for psychiatric illnesses, the gut microbiome, and probiotics. All results were then evaluated based on specific eligibility criteria. Results Eight studies met eligibility criteria and were analyzed for reported changes in outcome measures used to assess the symptoms of psychiatric illness and the tolerability of treatment. All Major Depressive Disorder (MDD) (n = 5) and Generalized Anxiety Disorder (GAD) (n = 1) studies found adjuvant probiotic or synbiotic treatment to be more efficacious in improving the symptoms of psychiatric illness than the first-line treatment alone or with placebo. The schizophrenia studies (n = 2) found adjuvant probiotic treatment to have no significant difference in clinical outcomes, but it was found to improve the tolerability of first-line antipsychotics. Discussion and conclusion The findings of the studies included in this review suggest the use of adjuvant probiotic treatment with selective serotonin reuptake inhibitors (SSRIs) for MDD and GAD to be superior to SSRI treatment alone. Probiotic adjuvant treatment with antipsychotics could be beneficial for improving the tolerability of the antipsychotics, but these findings do not suggest that adjuvant probiotic treatment would result in improved clinical outcomes for symptoms of schizophrenia.
Collapse
Affiliation(s)
- Evan Forth
- Department of Psychiatry, Providence Care Hospital, Kingston, ON, Canada,Centre for Neuroscience Studies, Queen’s University, Kingston, ON, Canada,Department of Psychiatry, Queen’s University, Kingston, ON, Canada,*Correspondence: Evan Forth,
| | - Benjamin Buehner
- Centre for Neuroscience Studies, Queen’s University, Kingston, ON, Canada
| | - Ana Storer
- Centre for Neuroscience Studies, Queen’s University, Kingston, ON, Canada
| | - Cassandra Sgarbossa
- Department of Psychiatry, Providence Care Hospital, Kingston, ON, Canada,Centre for Neuroscience Studies, Queen’s University, Kingston, ON, Canada,Department of Psychiatry, Queen’s University, Kingston, ON, Canada
| | - Roumen Milev
- Department of Psychiatry, Providence Care Hospital, Kingston, ON, Canada,Centre for Neuroscience Studies, Queen’s University, Kingston, ON, Canada,Department of Psychiatry, Queen’s University, Kingston, ON, Canada,Department of Psychology, Queen’s University, Kingston, ON, Canada
| | - Arthi Chinna Meyyappan
- Department of Psychiatry, Providence Care Hospital, Kingston, ON, Canada,Centre for Neuroscience Studies, Queen’s University, Kingston, ON, Canada,Department of Psychiatry, Queen’s University, Kingston, ON, Canada
| |
Collapse
|
3
|
Pendyala V, Thakur SR, Yadikar L, Chinta MD. Chrysin Attenuates Chronic Unpredictable Mild Stress Induced Changes in Behavior, Inflammation and Improves Adrenergic, Serotonergic Function: An <i>In-vivo</i> and Biochemical Study. Toxicol Int 2022. [DOI: 10.18311/ti/2022/v29i3/29153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Chrysin (5,7-dihydroxyflavone) is a flavonoid with a vast number of pharmacological properties because of its antioxidant potential. Chronic stress is one of the predominant etiological factors which evoke molecular alterations in the brain leading to the development of depressive disorder. In the present study, we investigated the effect of Chrysin on Chronic Unpredictable Mild Stress (CUMS) induced alterations in behavior, noradrenergic as well as serotonergic function, and inflammation in brain. Randomly, mice were divided into four groups of six animals in each group. On 28th day after assessing behavioral parameters, brain biochemical markers were assessed. From the results, it is concluded that the chrysin protects the brain cells from CUMS induced molecular changes by attenuation of inflammation and oxidative stress.
Collapse
|
4
|
Mohammadi S, Zandi M, Dousti Kataj P, Karimi Zandi L. Chronic stress and Alzheimer's disease. Biotechnol Appl Biochem 2021; 69:1451-1458. [PMID: 34152660 DOI: 10.1002/bab.2216] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Accepted: 06/18/2021] [Indexed: 12/17/2022]
Abstract
Stress is a key factor in the development and progress of diseases. In neurodegenerative conditions, stress management can play an important role in maintaining the quality of life and the capacity to improve. Neurodegenerative diseases, including Alzheimer's disease, cause the motor and cognitive malfunctions that are spontaneously stressful and also can disturb the neural circuits that promote stress responses. The interruption of those circuits leads to aggressive and inappropriate behavior. In addition, stress contributes to illness and may exacerbate symptoms. In this review, we present stress-activated neural pathways involved in Alzheimer's disease from a clinical and experimental point of view, as well as supportive drugs and therapies.
Collapse
Affiliation(s)
- Shima Mohammadi
- Neuroscience and Addiction Studies Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Milad Zandi
- Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Parviz Dousti Kataj
- Neuroscience and Addiction Studies Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Leila Karimi Zandi
- Neuroscience and Addiction Studies Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
5
|
Forchuk C, Nazarov A, Hunt R, Davis B, St Cyr K, Richardson JD. The influence of depression-PTSD comorbidity on health-related quality of life in treatment-seeking veterans. Eur J Psychotraumatol 2020; 11:1748460. [PMID: 32922680 PMCID: PMC7448842 DOI: 10.1080/20008198.2020.1748460] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
OBJECTIVE Posttraumatic stress disorder (PTSD) and depression substantially impair health-related quality of life (HRQOL) for many Canadian Armed Forces (CAF) veterans. Although PTSD and depression are highly comorbid, little is known about whether the disorders may interact in their association with HRQOL. We sought to investigate whether depressive symptoms modify the relation between PTSD and HRQOL in treatment-seeking veterans. METHOD We accessed the clinical data of 545 CAF veterans aged 18 to 65 years who were seeking treatment at a specialized clinic in London, Ontario. We used hierarchical linear regression to assess the additive and multiplicative relations between depression and PTSD symptoms on HRQOL, controlling for age and alcohol/substance abuse. Simple slopes were examined to probe significant interactions. RESULTS Probable PTSD and major depression were present in 77.4% and 85.3% of the sample, respectively, and 73.0% of the sample presented with probable PTSD-depression comorbidity. Depression symptoms significantly modified the relation between PTSD symptoms and overall mental HRQOL (β = 0.12, p <0.001, ∆R2 = 0.014), and role impairment due to emotional difficulties (β = 0.20, p <0.001, ∆R2 = 0.035). Simple slope analyses revealed the impact of PTSD was greater among those with lower depression symptoms and became weaker with greater depression symptom severity. In adjusted models, only depression was significantly associated with all mental and physical HRQOL domains; PTSD was not associated with physical HRQOL, role emotional impairment, or vitality. CONCLUSIONS For those with severe comorbid depression, PTSD symptoms were no longer associated with mental HRQOL, particularly in areas related to emotional functioning. Findings suggest the importance of targeting depression in patients presenting with PTSD-depression comorbidity.
Collapse
Affiliation(s)
- Callista Forchuk
- The MacDonald Franklin OSI Research Centre, Parkwood Institute, St. Joseph's Health Care, London, Ontario, Canada
| | - Anthony Nazarov
- The MacDonald Franklin OSI Research Centre, Parkwood Institute, St. Joseph's Health Care, London, Ontario, Canada.,Department of Psychiatry, Western University, London, Ontario, Canada.,Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
| | - Renee Hunt
- The MacDonald Franklin OSI Research Centre, Parkwood Institute, St. Joseph's Health Care, London, Ontario, Canada.,Department of Psychiatry, Western University, London, Ontario, Canada
| | - Brent Davis
- The MacDonald Franklin OSI Research Centre, Parkwood Institute, St. Joseph's Health Care, London, Ontario, Canada.,Computer Science Department, Western University, London, Ontario, Canada
| | - Kate St Cyr
- The MacDonald Franklin OSI Research Centre, Parkwood Institute, St. Joseph's Health Care, London, Ontario, Canada.,Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - J Don Richardson
- The MacDonald Franklin OSI Research Centre, Parkwood Institute, St. Joseph's Health Care, London, Ontario, Canada.,Department of Psychiatry, Western University, London, Ontario, Canada.,Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada.,OSI Clinic, Parkwood Institute, St. Joseph's Health Care, London, Ontario, Canada
| |
Collapse
|
6
|
Sakurai M, Yamamoto Y, Kanayama N, Hasegawa M, Mouri A, Takemura M, Matsunami H, Miyauchi T, Tokura T, Kimura H, Ito M, Umemura E, Boku AS, Nagashima W, Tonoike T, Kurita K, Ozaki N, Nabeshima T, Saito K. Serum Metabolic Profiles of the Tryptophan-Kynurenine Pathway in the high risk subjects of major depressive disorder. Sci Rep 2020; 10:1961. [PMID: 32029791 PMCID: PMC7005270 DOI: 10.1038/s41598-020-58806-w] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 01/21/2020] [Indexed: 12/31/2022] Open
Abstract
Previous reports have shown that during chronic inflammation, the tryptophan (TRP)-kynurenine (KYN) pathway plays a pivotal role in the onset of depression. The aim of this study was to investigate the characteristics of the serum TRP-KYN pathway metabolite profile in high-risk subjects of major depressive disorder (HRMDD) defined by depression scores. The concentrations of TRP-KYN pathway metabolites {TRP, KYN, 3-hydroxyanthranilic acid (3HAA), 3-hydroxykynurenine (3HK), kynurenic acid (KYNA) and anthranilic acid (AA)} were assessed in serum from HRMDD, chronic pain disorder patients and healthy controls. In serum from HRMDD, elevated levels of AA and decreased levels of TRP were observed, but the levels of other metabolites were not changed. Furthermore, the change in the AA2nd/AA1st ratio in subjects who progressed from a health. y state to a depressive state was correlated with an increase in the CES-D score. The level of IL-1 receptor antagonist (IL-1RA) was negatively correlated with that of AA. Interestingly, we confirmed AA as a possible biomarker for depression-related symptoms, since the metabolite profiles in the chronic pain disorder group and chronic unpredictable mild stress model mice were similar to those in the HRMDD. These results suggest that AA may be an effective marker for HRMDD.
Collapse
Affiliation(s)
- Masashi Sakurai
- Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Yasuko Yamamoto
- Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, 606-8507, Japan. .,Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan.
| | - Noriyo Kanayama
- Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Masaya Hasegawa
- Department of Regulatory Science, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan
| | - Akihiro Mouri
- Department of Regulatory Science, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan.,Japanese Drug Organization of Appropriate Use and Research, Nagoya, 468-0069, Japan
| | - Masao Takemura
- Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan
| | | | - Tomoya Miyauchi
- Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Tatsuya Tokura
- Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Hiroyuki Kimura
- Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Mikiko Ito
- Department of Oral and Maxillofacial, Surgery, School of Dentistry, Aichi Gakuin University, Nagoya, 470-0195, Japan
| | - Eri Umemura
- Department of Oral and Maxillofacial, Surgery, School of Dentistry, Aichi Gakuin University, Nagoya, 470-0195, Japan
| | - Aiji Sato Boku
- Department of Anesthesiology, Aichi Gakuin, University, Nagoya, 470-0195, Japan
| | - Wataru Nagashima
- Department of Psychopathology and Psychotherapy/Center for Student Counseling, Nagoya University, Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Takashi Tonoike
- Faculty of Psychological and Physical Sciences, Health Service Center, Aichi Gakuin University, Nisshin, Japan
| | - Kenichi Kurita
- Department of Oral and Maxillofacial, Surgery, School of Dentistry, Aichi Gakuin University, Nagoya, 470-0195, Japan
| | - Norio Ozaki
- Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Toshitaka Nabeshima
- Japanese Drug Organization of Appropriate Use and Research, Nagoya, 468-0069, Japan.,Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan
| | - Kuniaki Saito
- Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, 606-8507, Japan.,Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan.,Japanese Drug Organization of Appropriate Use and Research, Nagoya, 468-0069, Japan
| |
Collapse
|
7
|
Kabiri M, Hemmatpour A, Zare F, Hadinedoushan H, Karimollah A. Paroxetine modulates immune responses by activating a JAK2/STAT3 signaling pathway. J Biochem Mol Toxicol 2020; 34:e22464. [DOI: 10.1002/jbt.22464] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2019] [Revised: 01/15/2020] [Accepted: 01/22/2020] [Indexed: 12/22/2022]
Affiliation(s)
- Mahdieh Kabiri
- Department of Pharmacology, School of Pharmacy Shahid Sadoughi University of Medical Sciences and Health Services Yazd Iran
| | - Anahid Hemmatpour
- Department of Biochemistry, School of Medicine Shahid Sadoughi University of Medical Sciences and Health Services Yazd Iran
| | - Fatemeh Zare
- Reproductive Immunology Research Center Shahid Sadoughi University of Medical Sciences and Health Services Yazd Iran
| | - Hossein Hadinedoushan
- Reproductive Immunology Research Center Shahid Sadoughi University of Medical Sciences and Health Services Yazd Iran
| | - Alireza Karimollah
- Department of Pharmacology, School of Pharmacy Shahid Sadoughi University of Medical Sciences and Health Services Yazd Iran
| |
Collapse
|
8
|
Abstract
Chronic low-grade inflammation has been observed in major depression and other major psychiatric disorders and has been implicated in metabolic changes that are commonly associated with these disorders. This raises the possibility that the effects of dysfunctional metabolism may facilitate changes in neuronal structure and function which contribute to neuroprogression. Such changes may have implications for the progress from major depression to dementia in the elderly patient. The purpose of this review is to examine the contribution of inflammation and hypercortisolaemia, which are frequently associated with major depression, to neurodegeneration and how they detrimentally impact on brain energy metabolism. A key factor in these adverse events is insulin insensitivity caused by pro-inflammatory cytokines in association with desensitised glucocorticoid receptors. Identifying the possible metabolic changes initiated by inflammation opens new targets to ameliorate the adverse metabolic changes. This has resulted in the identification of dietary and drug targets which are of interest in the development of a new generation of psychotropic drugs.
Collapse
|
9
|
Bansal Y, Singh R, Parhar I, Kuhad A, Soga T. Quinolinic Acid and Nuclear Factor Erythroid 2-Related Factor 2 in Depression: Role in Neuroprogression. Front Pharmacol 2019; 10:452. [PMID: 31164818 PMCID: PMC6536572 DOI: 10.3389/fphar.2019.00452] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2018] [Accepted: 04/09/2019] [Indexed: 12/14/2022] Open
Abstract
Depression is an incapacitating neuropsychiatric disorder. The serotonergic system in the brain plays an important role in the pathophysiology of depression. However, due to delayed and/or poor performance of selective serotonin reuptake inhibitors in treating depressive symptoms, the role of the serotonergic system in depression has been recently questioned further. Evidence from recent studies suggests that increased inflammation and oxidative stress may play significant roles in the pathophysiology of depression. The consequences of these factors can lead to the neuroprogression of depression, involving neurodegeneration, astrocytic apoptosis, reduced neurogenesis, reduced plasticity (neuronal and synaptic), and enhanced immunoreactivity. Specifically, increased proinflammatory cytokine levels have been shown to activate the kynurenine pathway, which causes increased production of quinolinic acid (QA, an N-Methyl-D-aspartate agonist) and decreases the synthesis of serotonin. QA exerts many deleterious effects on the brain via mechanisms including N-methyl-D-aspartate excitotoxicity, increased oxidative stress, astrocyte degeneration, and neuronal apoptosis. QA may also act directly as a pro-oxidant. Additionally, the nuclear translocation of antioxidant defense factors, such as nuclear factor (erythroid-derived 2)-like 2 (Nrf2), is downregulated in depression. Hence, in the present review, we discuss the role of QA in increasing oxidative stress in depression by modulating the nuclear translocation of nuclear factor (erythroid-derived 2)-like 2 and thus affecting the synthesis of antioxidant enzymes.
Collapse
Affiliation(s)
- Yashika Bansal
- Pharmacology Research Lab, University Institute of Pharmaceutical Sciences UGC-Centre of Advanced Study, Panjab University, Chandigarh, India
| | - Raghunath Singh
- Pharmacology Research Lab, University Institute of Pharmaceutical Sciences UGC-Centre of Advanced Study, Panjab University, Chandigarh, India
| | - Ishwar Parhar
- Brain Research Institute Monash Sunway, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia
| | - Anurag Kuhad
- Pharmacology Research Lab, University Institute of Pharmaceutical Sciences UGC-Centre of Advanced Study, Panjab University, Chandigarh, India
| | - Tomoko Soga
- Brain Research Institute Monash Sunway, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia
| |
Collapse
|
10
|
Dedeogullari E, Paholpak P, Barkoh K, Lucas J, Lee L, Wang C, Hsieh PC, Wang JC, Buser Z. Effect of mental health on post -operative infection rates following cervical spine fusion procedures. J Orthop 2017; 14:501-506. [PMID: 28855766 DOI: 10.1016/j.jor.2017.08.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 08/06/2017] [Indexed: 10/19/2022] Open
Abstract
PURPOSE The aim of this study was to determine whether having an existing psychiatric disorder is a risk factor for developing post-operative infection following anterior cervical discectomy with fusion (ACDF) and posterior cervical fusion (PCF). RESULTS A total of 34,007 patients within Humana database was included in this study. Patients with mental disorders had post-operative infection rates of 3.2% and 4.4% within 1 and 3months, compared to 2.5% and 3.5% in patients without a psychiatric disorder (p < 0.05). CONCLUSIONS Patients with mental disorders had significantly higher rates of post-operative infection compared to patients who were never diagnosed with a psychiatric disorder.
Collapse
Affiliation(s)
- Emin Dedeogullari
- Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Permsak Paholpak
- Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Kaku Barkoh
- Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Joshua Lucas
- Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Larry Lee
- Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Christopher Wang
- Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Patrick C Hsieh
- Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Jeffrey C Wang
- Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Zorica Buser
- Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|
11
|
Reig-Ferrer A, Ferrer-Cascales R, Santos-Ruiz A, Campos-Ferrer A, Prieto-Seva A, Velasco-Ruiz I, Fernandez-Pascual MD, Albaladejo-Blazquez N. A relaxation technique enhances psychological well-being and immune parameters in elderly people from a nursing home: a randomized controlled study. Altern Ther Health Med 2014; 14:311. [PMID: 25151398 PMCID: PMC4153914 DOI: 10.1186/1472-6882-14-311] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Accepted: 08/18/2014] [Indexed: 12/02/2022]
Abstract
Background The aging process involves a decline in immune functioning that renders elderly people more vulnerable to disease. In residential programs for the aged, it is vital to diminish their risk of disease, promote their independence, and augment their psychological well-being and quality of life. Methods We performed a randomized controlled study, evaluating the ability of a relaxation technique based on Benson’s relaxation response to enhance psychological well-being and modulate the immune parameters of elderly people living in a geriatric residence when compared to a waitlist control group. The study included a 2-week intervention period and a 3-month follow-up period. The main outcome variables were psychological well-being and quality of life, biomedical variables, immune changes from the pre-treatment to post-treatment and follow-up periods. Results Our findings reveal significant differences between the experimental and control groups in CD19, CD71, CD97, CD134, and CD137 lymphocyte subpopulations at the end of treatment. Furthermore, there was a decrease in negative affect, psychological discomfort, and symptom perception in the treatment group, which increased participants’ quality of life scores at the three-month follow-up. Conclusions This study represents a first approach to the application of a passive relaxation technique in residential programs for the elderly. The method appears to be effective in enhancing psychological well-being and modulating immune activity in a group of elderly people. This relaxation technique could be considered an option for achieving health benefits with a low cost for residential programs, but further studies using this technique in larger samples of older people are needed to confirm the trends observed in the present study. Trial registration International Standard Randomised Controlled Trial Number Register ISRCTN85410212
Collapse
|
12
|
Leonard BE. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48:261-7. [PMID: 24189118 DOI: 10.1016/j.pnpbp.2013.10.018] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Accepted: 10/28/2013] [Indexed: 12/11/2022]
Abstract
This review summarises the evidence that chronic low grade inflammation plays an important role in the pathology of depression. Evidence is provided that pro-inflammatory cytokines, together with dysfunctional endocrine and neurotransmitter systems, provide a network of changes that underlie depression and may ultimately contribute to the neurodegenerative changes that characterise depression in the elderly. Antidepressants attenuate the inflammatory changes and hypercortisolaemia by reducing the release of the pro-inflammatory cytokines from activated microglia, and by sensitizing the glucocorticoids receptors in the HPA axis. These effects correlate with an improvement in monoamine neurotransmitter function. The possible mechanisms whereby this cascade of changes occurs are outlined. In conclusion, the mechanisms whereby antidepressants act should now consider the involvement of the immune and endocrine systems in addition to the central neurotransmitters. This may open up possibilities for a new generation of antidepressants in the future.
Collapse
|